
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
Hospitals must meet new standards the Joint Commission has set up for 2009.
The Joint Commission’s just-released
To see more Daily News articles,
To go to the Drug Topics homepage,






